Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
P/E ratio for Ovid Therapeutics Inc. (OVID)
P/E ratio as of 2023: -4.34
According to Ovid Therapeutics Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.34. At the end of 2022 the company had a P/E ratio of -2.55.
P/E ratio history for Ovid Therapeutics Inc. from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.34 |
| 2022 | -2.55 |
| 2021 | 1.76 |
| 2020 | -1.67 |
| 2019 | -2.75 |
| 2018 | -1.15 |
| 2017 | -2.95 |
| 2016 | -10.71 |
| 2015 | -18.25 |
| 2014 | -130.29 |